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Abstract
BACKGROUND—Cancer survivors may experience long-term and late effects from treatment 
that adversely affect health and limit functioning. Few studies examine lost productivity and 
disease burden in cancer survivors compared with individuals who have other chronic conditions 
or by cancer type.
METHODS—We identified 4960 cancer survivors and 64,431 other individuals from the 2008–
2010 Medical Expenditure Panel Survey and compared multiple measures of disease burden, 
including health status and lost productivity, between conditions and by cancer site for cancer 
survivors. All analyses controlled for the effects of age, sex, race/ethnicity, and number of 
comorbid conditions.
RESULTS—Overall, in adjusted analyses in multiple models, cancer survivors with another 
chronic disease (heart disease or diabetes) experienced higher levels of burden compared with 
individuals with a history of cancer only, chronic disease only, and neither cancer, heart disease, 
nor diabetes across multiple measures (P <.05). Among cancer survivors, individuals with short 
survival cancers and multiple cancers consistently had the highest levels of burden across multiple 
measures (P <.0001).
CONCLUSIONS—Cancer survivors who have another chronic disease experience more 
limitations and higher levels of burden across multiple measures. Limitations are particularly 
severe in cancer survivors with short survival cancer and multiple cancers.
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INTRODUCTION
As of 2009, there were nearly 13 million cancer survivors in the United States,1 and this 
number is projected to increase.2 Cancer survivors may experience long-term and late effects 
from their treatment that adversely affect their health and limit functioning and productivity, 
even many years after treatment.3,4 However, many studies of lost productivity and disease 
burden in cancer survivors have limited follow-up, have small sample sizes, or have been 
limited to a single cancer type.5,6 Although several older studies have used large national, 
population-based data to overcome these limitations,7,8 more recent national estimates are 
needed to understand the current impact on cancer survivors’ health and functioning. 
Treatment advances have improved cancer survival, but the prevalence of late effects have 
likely increased as well.9 Furthermore, available studies do not compare cancer survivors 
with individuals who have other medical conditions, making it challenging to understand 
how the burden from cancer compares to the impact of other chronic diseases in the United 
States adult population.5
A recent Institute of Medicine report highlights the need for research to assess health and 
functional status for individuals living with chronic illness.3 Furthermore, understanding the 
burden of cancer by specific cancer type is needed, because different treatments may lead to 
variations in outcomes.10,11 However, prior work in cancer survivors and comorbidities has 
been conducted primarily in the elderly population,11,12 which limits the ability to assess 
burden of illness from cancer on employment and other productivity measures. To address 
these research gaps, we 1) used national data to estimate disease burden by examining 
health, functional status, and lost productivity in cancer survivors and individuals without a 
history of cancer to understand how these burden and limitations estimates compare with the 
burden caused by other major chronic diseases in the United States and 2) compared burden 
of illness by cancer site to provide estimates for subgroups of the United States cancer 
survivor population.
MATERIALS AND METHODS
Data Source
The study sample was selected from the 2008–2010 Medical Expenditure Panel Survey 
(MEPS) Household Component. The MEPS is an annual, nationally representative survey 
conducted in the civilian noninstitutionalized population in the United States. The MEPS 
Household Component collects demographic, health status, employment, and health care use 
and medical expenditure data. It also collects information about medical conditions that have 
been specified as priority conditions due to prevalence, expense, or policy relevance. In-
person interviews are conducted with an individual who responds for all household 
members. The average annual response rate was approximately 57%. More detailed 
information on the MEPS design and content has been provided elsewhere.13
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Analytic Sample
We identified 69,391 adults aged ≥18 years. To make comparisons between cancer survivors 
and individuals with other chronic conditions, we categorized individuals into the following 
groups: having a personal history of cancer, having a personal history of heart disease, and 
having a personal history of diabetes. These groups were not mutually exclusive. These 
diseases were selected due to the prevalence and expense of these conditions in the United 
States population.14 Conditions were identified by questions asking whether a doctor or 
other health professional had ever told the person they had any of the MEPS priority 
conditions (arthritis, asthma, angina, cancer, coronary heart disease, diabetes, emphysema, 
heart attack, high blood pressure, high cholesterol, and stroke). For the history of cancer 
category, we excluded individuals diagnosed with only nonmelanoma skin cancer, as has 
been done elsewhere.8,15 We classified individuals with a history of coronary heart disease, 
angina, heart attack, stroke, or “other heart disease” as having a history of heart disease.16 
The history of diabetes category included individuals who indicated they had a history of 
this condition. We also categorized cancer survivors by cancer site (breast, prostate, 
colorectal, short survival cancers, multiple cancers, and other single cancers). Short survival 
cancers were defined as those with a 5-year survival rate of <25% and included liver, lung, 
pancreas, and stomach cancers.
Measures
Sample characteristics included age, sex, educational attainment, and race/ethnicity. 
Comorbid conditions were defined as known MEPS priority conditions (0, 1, 2, 3+) other 
than the primary conditions of the individual (ie, cancer, heart disease, or diabetes).
Health and functional limitation measures consisted of health status (excellent/very good, 
good, fair/poor); any limitations in physical functioning; and limitations in physical 
functioning that lasted for more than 3 months.
Lost productivity measures included whether the individual was employed within the past 12 
months for individuals <65 years of age. We also measured any limitations among all 
individuals’ ability to work, do housework, or go to school because of a health problem; 
inability to do activities; and experience of cognitive limitations. Other measures included 
whether individuals accomplished less due to their physical health in the last 4 weeks or 
were limited in the kind of work or activities they engaged in due to their physical health in 
the last 4 weeks. Each health and lost productivity construct was obtained with a single item.
Data Analyses
Descriptive statistics were stratified by history of cancer and were compared using chi-
square statistics. To compare health and functional status, employment, and lost productivity 
by chronic disease type, we used multivariate logistic regression in separate samples defined 
by history of cancer and 1) heart disease and 2) diabetes and controlled for the effects of age, 
race/ethnicity, sex, and comorbidities defined as number of other known MEPS priority 
conditions. We focused our discussion of results on consistent patterns of findings across 
multiple measures, rather than adjusting statistical significance thresholds for multiple 
comparisons. Results of the regression analyses are presented as predicted margins, which 
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directly standardize the outcome of each group to the covariate distribution of the 
population.17 Standardized results from logit models can be compared like percentages and 
allow for ease of interpretation. All analyses used SUDAAN18 to account for the MEPS 
survey weights and complex design. Wald statistics were used to test the statistical 
significance of differences between groups, and all tests of statistical significance were 2-
sided. We calculated 95% confidence intervals for the predicted margins using a logit 
transformation.17
RESULTS
The characteristics of the study subjects are presented in Table 1. Individuals with a history 
of cancer were more likely to be older, female, and non-Hispanic white and were more likely 
to report having 3 or more other MEPS priority conditions compared with individuals 
without cancer (P <.001).
GENERAL HEALTH, FUNCTIONAL STATUS AND LOST PRODUCTIVITY BY 
CHRONIC DISEASE HISTORY
Figure 1 displays health status in individuals with and without a history of cancer, heart 
disease, or diabetes. Overall, individuals who had a history of cancer plus history of heart 
disease or diabetes were more likely to have fair/poor health compared with individuals who 
had a history of cancer, history of heart disease or diabetes, or none of these conditions in 
separate multivariate analyses (P <.05).
Table 2 presents functional status and lost productivity by chronic disease history. 
Individuals with a history of cancer plus another chronic disease had poorer functional status 
than individuals with a history of cancer or a history of another chronic disease, or without 
cancer or the other chronic conditions, across multiple measures.
With respect to employment status, adults <65 years of age with a history of cancer plus 
heart disease were less likely to be employed in the past 12 months compared with 
individuals who had a history of cancer or heart disease or individuals without a history of 
cancer or heart disease in adjusted models (65.5%, 77.4%, 74.1, and 82.3%, respectively; P 
<.0001). Results were similar for individuals with a history of diabetes. Other measures of 
lost productivity also followed a similar pattern across multiple measures for the majority of 
the heart disease and diabetes comparisons (P <.001).
Within the heart disease and diabetes comparisons, individuals with a history of cancer plus 
another chronic disease were the most likely to accomplish less because of their physical 
health (Fig. 2A) and be more limited in the kind of work or activities they engaged in 
because of physical health in the past 4 weeks (Fig. 2B) compared with individuals who had 
specific chronic disease, cancer, or neither cancer nor other chronic disease in adjusted 
analyses (P <.05).
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GENERAL HEALTH, FUNCTIONAL STATUS AND LOST PRODUCTIVITY BY 
CANCER SITE
In adjusted analyses, individuals with a history of cancer, particularly those with a history of 
short survival cancers or multiple cancers, had poorer health and greater productivity loss 
across multiple measures compared with individuals without cancer (Table 3; P <.05). 
Generally, adults with a history of breast cancer were least likely to have limitations and 
were more similar to individuals without cancer across these measures.
Compared with individuals who had a history of other single cancers or had no history of 
cancer, individuals with a history of short survival cancers or multiple cancers were most 
likely to accomplish less (Fig. 3A; P <.0001) and be limited in the kind of work or activities 
they engaged in due to their physical health (Fig. 3B; P <.0001) in the past 4 weeks.
DISCUSSION
In this study, we used a nationally representative sample to assess health status, employment, 
and lost productivity in cancer survivors compared with adults with and without other 
chronic diseases. The goals of our study were to provide current population-based estimates 
of health status and lost productivity for cancer survivors compared with individuals without 
cancer to 1) understand how these estimates compare with the burden caused by other major 
chronic diseases in the United States, 2) understand any additional impact of specific 
comorbidity for cancer survivors, and 3) examine these measures by specific cancer sites. 
This study was conducted using the most recently available data in a sample of adults ≥18 
years of age, complementing previous studies of comorbidities in cancer survivors that were 
primarily conducted in the elderly population.19
As expected, we found that cancer survivors continue to experience significant levels of 
burden, and that having an additional history of heart disease or diabetes is associated with 
even greater burden. While other studies have documented poorer outcomes, diminished 
physical capacity and productivity of cancer survivors,5,7 few have provided estimates of 
these outcomes in cancer survivors with and without other types of chronic disease.
These findings help contextualize the estimates for cancer survivors more broadly to the 
burden caused by other chronic diseases in the United States. Notably, the increased burden 
and limitations for cancer survivors appear similar for survivors who additionally have either 
heart disease or diabetes, possibly suggesting a generalized disease effect of multiple 
comorbidities. These findings underscore the value of working across chronic diseases in 
clinical care and preventive services, especially due to the growing population of cancer 
survivors who are older adults and at risk for multiple comorbidities.3,20 There is ongoing 
debate regarding the best models of care to meet cancer survivors’ needs.21 This study 
highlights the importance of assessing and managing other comorbidities as part of 
survivorship care, especially our findings that suggest 37% of cancer survivors also have a 
history of heart disease and 17% have a history of diabetes. Given the observed functional 
limitations for cancer survivors and individuals with a history of other chronic diseases, 
applying evidence-based interventions or models of care from other disease models (eg, 
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cardiac care’s rehabilitation approach)20 may improve cancer care delivery and quality of 
life in cancer survivors.
Consistent with other studies,7,8 we observed that employment, lost productivity, and burden 
of illness vary substantially across subgroups of cancer survivors. However, our findings 
provide current estimates of burden and productivity losses by cancer type for cancer 
survivors. As expected, survivors with cancers associated with short survival or who had 
multiple cancers consistently had the highest levels of burden compared with other single 
site cancers. Approximately 320,120 people in the United States are diagnosed with liver, 
lung, pancreas, or stomach cancers,1 and at least 750,000 people are diagnosed with multiple 
cancers, accounting for almost 8% of the overall cancer survivorship population.22 While 
our results were consistent with the few population-based studies on individuals with 
multiple cancer diagnoses,15,23 more research is needed to measure and understand the 
burden of illness in individuals with multiple cancer diagnoses, particularly as they become 
more prevalent with improved survival following diagnosis,24 increased risk of second 
cancers associated with treatment,9 and the aging population.22
Our results also indicate that breast cancer survivors had the lowest levels of burden reported 
among cancer survivors and are similar on many measures to adults without cancer. In our 
sample, breast cancer survivors were generally younger than other cancer survivors, and a 
substantial proportion were long-term survivors (ie, greater than 10 years since diagnosis). 
These variations in burden of illness and limitations in cancer survivors across cancer site 
highlight the importance of detailed examination by specific cancer sites, particularly as 
cancer treatment becomes more specified for individuals, which may result in differing 
outcomes.
Therefore, our findings suggest that significant levels of burden and limitations persist after 
treatment among cancer survivors that affect physical functioning and ability to work or 
perform usual activities. Notably, approximately 30% of cancer survivors accomplished less 
in the past 4 weeks or were limited in work or usual activities because of physical health, 
with about 12% being limited all the time. Several approaches have been developed to 
quantify the impact of activity limitations, including wage- and preference-based approaches 
to valuing time.25 Further development and application of approaches to quantifying 
limitations in productivity will improve our current understanding of disease burden in 
cancer survivors, including costs of care and financial issues. Helping inform future 
research, the MEPS Experiences with Cancer Survivorship Supplement will provide 
nationally representative data to address many of these issues.26
Despite the strengths of having a large population-based sample and the ability to assess 
multiple chronic diseases, there are several limitations to this study. We were unable to 
assess some commonly diagnosed cancer sites separately, such as lung cancer, due to shorter 
survival and therefore limited sample size. However, we were able to group several cancer 
types associated with short survival separately and evaluate burden for these individuals. 
Data on history of cancer and chronic disease were based on self-report or household proxy; 
however, validation studies have found strong agreement between household-reported and 
physician-reported conditions.27 Although false positive reports of cancer and other chronic 
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diseases are low,28 some individuals with a history of cancer, heart disease or diabetes may 
have been classified in the other comparison group (ie, false negative reports), which may 
have underestimated the differences between these groups.29 Additionally, we could not 
assess the severity of the diseases reported, and cancer stage or treatment information was 
not available. Because of our interest in evaluating multiple measures of burden for 
individuals with and without heart disease or diabetes, we conducted many separate 
analyses. Finally, the cancer survivor population was disproportionately older and non-
Hispanic white compared with the population of individuals without a history of cancer. 
Future studies should replicate these findings among more diverse populations of cancer 
survivors.
In conclusion, we observed that cancer survivors continue to experience significant burden 
of illness across multiple measures of productivity and functioning. Additionally, cancer 
survivors who have an additional chronic disease generally experience higher levels of 
burden compared with other individuals. We also identify cancer survivors who might be at 
higher risk for functional limitations and inform efforts to develop more efficacious and 
targeted interventions.8,10,11
Acknowledgments
FUNDING SOURCES
No specific funding was disclosed.
References
1. Howlader, N., Noone, A., Krapcho, M., et al. SEER cancer statistics review, 1975–2009 (vintage 
2009 populations). National Cancer Institute; Bethesda, MD: Available at: http://seer.cancer.gov/csr/
1975_2009_pops09/ [Accessed June 5, 2012]
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in 
the United States: 2010–2020. J Natl Cancer Inst. 2011; 103:117–128. [PubMed: 21228314] 
3. Institute of Medicine. Living well with chronic illness: a call for public health action. Washington, 
DC: Institute of Medicine; 2012. 
4. Ness KK, Wall MM, Oakes JM, Robison LL, Gurney JG. Physical performance limitations and 
participation restrictions among cancer survivors: a population-based study. Ann Epidemiol. 2006; 
16:197–205. [PubMed: 16137893] 
5. Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT. Symptom burden among cancer 
survivors: impact of age and comorbidity. J Am Board Fam Med. 2007; 20:434–443. [PubMed: 
17823460] 
6. Yabroff KR, McNeel TS, Waldron WR, et al. Health limitations and quality of life associated with 
cancer and other chronic diseases by phase of care. Med Care. 2007; 45:629–637. [PubMed: 
17571011] 
7. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. 
J Gerontol A Biol Sci Med Sci. 2003; 58:82–91. [PubMed: 12560417] 
8. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer 
survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004; 96:1322–
1330. [PubMed: 15339970] 
9. Institute of Medicine. From cancer patient to cancer survivor: lost in transition. Washington, DC: 
Institute of Medicine; 2005. 
10. Avis NE, Deimling GT. Cancer survivorship and aging. Cancer. 2008; 113(12 suppl):3519–3529. 
[PubMed: 19058151] 
Dowling et al. Page 7
Cancer. Author manuscript; available in PMC 2018 March 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11. Bellizzi KM, Mustian KM, Palesh OG, Diefenbach M. Cancer survivorship and aging: moving the 
science forward. Cancer. 2008; 113(12 suppl):3530–3539. [PubMed: 19058147] 
12. Smith AW, Reeve BB, Bellizzi KM, et al. Cancer, comorbidities, and health-related quality of life 
of older adults. Health Care Financ Rev. 2008; 29:41–56. [PubMed: 18773613] 
13. Agency for Healthcare Research and Quality. [Accessed June 20, 2012] MEPS survey background. 
Available at: http://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp
14. Agency for Healthcare Research and Quality. [Accessed March 13, 2013] Total expenses and 
percent distribution for selected conditions by source of payment: United States, 2010. Medical 
Expenditure Panel Survey Household Component Data. Generated interactively. http://
meps.ahrq.gov/data_stats/tables_compendia_hh_interactive.jsp?
_SERVICE=MEPSSocket0&_PROGRAM=MEPSPGM.TC.SAS&File=HCFY2010&Table=HCF
Y2010_CNDXP_D&_Debug=
15. Andrykowski MA. Physical and mental health status of survivors of multiple cancer diagnoses: 
findings from the national health interview survey. Cancer. 2012; 118:3645–3653. [PubMed: 
22170497] 
16. Soni, A. Aspirin use among the adult U.S. noninstitutionalized population, with and without 
indicators of heart disease, 2005. Statistical Brief #179. Available at: http://meps.ahrq.gov/
mepsweb/data_files/publications/st179/stat179.shtml
17. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999; 55:652–659. 
[PubMed: 11318229] 
18. Research Triangle Institute. SUDAAN language manual: release 9.0. 2004. 
19. Keating NL, Norredam M, Landrum MB, Huskamp HA, Meara E. Physical and mental health 
status of older long-term cancer survivors. J Am Geriatr Soc. 2005; 53:2145–2152. [PubMed: 
16398900] 
20. Alfano CM, Ganz PA, Rowland JH, Hahn EE. Cancer survivorship and cancer rehabilitation: 
revitalizing the link. J Clin Oncol. 2012; 30:904–906. [PubMed: 22355063] 
21. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006; 24:5117–
5124. [PubMed: 17093273] 
22. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing 
challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007; 16:566–571. 
[PubMed: 17372253] 
23. Burris JL, Andrykowski MA. Physical and mental health status and health behaviors of survivors 
of multiple cancers: a national, population-based study. Ann Behav Med. 2011; 42:304–312. 
[PubMed: 21732227] 
24. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, 
with a special feature regarding survival. Cancer. 2004; 101:3–27. [PubMed: 15221985] 
25. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl 
Cancer Inst. 2007; 99:14–23. [PubMed: 17202109] 
26. Yabroff K, Dowling E, Rodriguez J, et al. The medical expenditure panel survey (MEPS) 
experiences with cancer survivorship supplement. J Cancer Surviv. 2012; 6:407–419. [PubMed: 
23011572] 
27. Krauss, N., Kass, B. Comparison of household and medical provider reports of medical conditions. 
Paper presented at: Joint Statistical Meetings; August 13–17, 2000; Indianapolis, IN. 
28. Harlow SD, Linet MS. Agreement between questionnaire data and medical records. The evidence 
for accuracy of recall. Am J Epidemiol. 1989; 129:233–248. [PubMed: 2643301] 
29. Desai MM, Bruce ML, Desai RA, Druss BG. Validity of self-reported cancer history: a comparison 
of health interview data and cancer registry records. Am J Epidemiol. 2001; 153:299–306. 
[PubMed: 11157418] 
Dowling et al. Page 8
Cancer. Author manuscript; available in PMC 2018 March 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
General health in individuals with and without a history of cancer, heart disease, and 
diabetes. Predicted margins were determined using logistic regression models with age, 
comorbidities, race/ethnicity, and sex as covariates (P <.05 [Wald test]). Abbreviations: CA, 
cancer; DB, diabetes; HD, heart disease.
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Figure 2. 
(A) Percent of individuals with and without a history of cancer, heart disease, and diabetes 
who accomplished less because of physical health in last 4 weeks. (B) Percent of individuals 
with and without a history of cancer, heart disease, and diabetes who had limited ability to 
work in last 4 weeks. Predicted margins were determined using logistic regression models 
with age, comorbidities, race/ethnicity, and sex as covariates (P <.05 [Wald test]). 
Abbreviations: CA, cancer; DB, diabetes; HD, heart disease.
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Figure 3. 
(A) Percent of individuals with and without a history of cancer who accomplished less 
because of physical health in last 4 weeks by cancer type. (B) Percent of individuals with 
and without a history of cancer who had limited ability to work in last 4 weeks by cancer 
type. Predicted margins were determined using logistic regression models with age, 
comorbidities, race/ethnicity, and sex as covariates (P <.05 [Wald test]).
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